CEO of Diaceutics, Peter Keeling shortlisted for Entrepreneur of the Year Award 2018 | Diaceutics

CEO of Diaceutics, Peter Keeling shortlisted for Entrepreneur of the Year Award 2018

  • He has been named as a finalist in the international category  
  • A total of 24 entrepreneurs are in the running for the coveted title 
  • The world-renowned programme has been running for 21 years 

Peter Keeling, founder and CEO of Irish company Diaceutics, has been announced as one of the finalists for this year’s EY Entrepreneur of the Year award.  

Now in its 21st year and celebrating the theme of ‘Ambition’, the world-renowned programme recognises Ireland’s high-growth business leaders.   

Peter, who founded Diaceutics in 2005, has been named as a finalist in the international category and joins 23 other entrepreneurs in the running for the coveted prize, the winner of which will be revealed in October.  

Diaceutics works with the world’s top pharmaceutical companies and utilises its global network of laboratories to help deliver better testing, more efficient diagnosis and more effective treatment for patients.  

Since inception, the organisation has given more than half a million patients with life-threatening diseases the best possible chance of getting better. It works in the top 10 markets in the world and has enjoyed 60% growth year-on-year for the last three years. 

Peter has driven the organisation since its inception, when he recognised early on the value of precision medicine in terms of drug development and patient care, to its position now as a leader in the industry.   

Speaking about the news, Peter Keeling said: “It is an absolute honour to be named as a finalist in the EY Entrepreneur of the Year programme, which is widely-recognised and well-respected across the globe. To be considered among such a high calibre of entrepreneurs and businesses is incredible.  

“This year’s ‘Ambition’ theme is something that resonates with everyone who works at Diaceutics and makes the achievement extra special. We are a very ambitious organisation which is constantly striving, and succeeding, at getting the right patients to the right treatment at the right time.” 

About Diaceutics
Diaceutics is the diagnostic development and commercialization service provider. We have been leading this field for 13 years, entirely focused on the intersection between diagnostics and therapeutic decision making. We provide an end to end service that encompasses everything from understanding the diagnostic landscape to test implementation in treatment pathways. This is all enabled by a robust flow of data from the Diaceutics global laboratory network. Our ultimate goal is to drive better testing to enable better treatment decisions for patients.

  • Proven global market leader with experience of 300+ precision medicine projects
  • We have helped launch 6 out of the last 12 targeted oncology brands
  • Extensive coverage of Top 10 global markets: US, France, Germany, UK, Italy, Spain, Brazil, China, Russia, Australia
  • Estimates indicate having improved testing for over 500,000 patients globally
  • We draw data from a global network of over 2,500 laboratories to facilitate diagnostic insights
  • We employ a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries

Media Contact
Rebecca McKnight
Tel: +353 1 215 7677
For more information, visit or follow Diaceutics on Twitter, LinkedIn or Facebook

Latest Blogs

Latest Blogs